$250K
+$250K this year1 filing since 2026 · latest SAFE filed
Sentrimed, Inc. is a clinical-stage biopharmaceutical company in Mullica Hill, New Jersey, based at the South Jersey Technology Park at Rowan University. It develops targeted cancer therapies aimed at podoplanin (PDPN), a transmembrane protein and prognostic biomarker that drives tumor proliferation, invasion, and migration. Its lead asset, MASL (lenipagrusin alfa), is an orally administered podoplanin inhibitor being developed initially for head and neck cancer. An NIH/National Cancer Institute-funded human trial run with Rowan University completed with no adverse events reported, and results announced in 2025 showed MASL inhibited cancer cell migration and viability in surgically removed head and neck tumors, including drug-resistant variants.
What sets it apart
MASL is a first-in-class oral podoplanin inhibitor: a single blockade acts across the RAS-GTP, TGF-beta/SMAD, JAK-STAT, and Wnt/beta-catenin pathways, reducing tumor growth and invasion while blocking immune evasion, and it induces necrotic tumor cell death that stimulates host anti-tumor immunity.
An orally administered small-molecule podoplanin (PDPN) inhibitor in clinical development, with head and neck cancer as the initial indication.
